4
Changes in Ownership
Xenon Pharmaceuticals Inc. Filed Acc 0001209191-22-048508
EVP, Strategy & Innovation sold 65,231 shares at an average $38.31 ($2,499,023)
- EVP, Strategy & Innovation acquired 72,488 shares (option exercise)
- EVP, Strategy & Innovation gave up 7,693 shares (to pay taxes)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-08-31 | Option exercise | +17,488 | $2.67 | $46,693 | 34,720 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-08-31 | Option exercise | +5,000 | $4.75 | $23,750 | 39,720 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-08-31 | Shares withheld for taxes | −1,572 | $37.86 | $59,516 | 38,148 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-08-31 | Sale | −21,352 | $38.57 | $823,547 | 16,796 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-09-01 | Option exercise | +50,000 | $4.75 | $237,500 | 66,796 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-09-01 | Shares withheld for taxes | −6,121 | $38.81 | $237,556 | 60,675 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-09-01 | Sale | −35,103 | $38.03 | $1,334,967 | 25,572 | D |
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-09-01 | Sale | −8,776 | $38.80 | $340,509 | 16,796 | D |
| Derivatives | |||||||
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-08-31 | Option exercise · Stock Options (Right to Buy) | −17,488 | 0 | D | ||
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-08-31 | Option exercise · Stock Options (Right to Buy) | −5,000 | 0 | D | ||
| ROBIN SHERRINGTON EVP, Strategy & Innovation | 2022-09-01 | Option exercise · Stock Option (Right to Buy) | −50,000 | 0 | D | ||
| Open-market sales · 65,231 sh · avg $38.31 · $2,499,023 | |||||||
Loading xslF345X03/doc4.xml…